Capital Investment Advisors LLC Takes Position in Becton, Dickinson and Company (NYSE:BDX)

Capital Investment Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,409 shares of the medical instruments supplier’s stock, valued at approximately $347,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Somerset Trust Co grew its holdings in shares of Becton, Dickinson and by 0.3% during the 1st quarter. Somerset Trust Co now owns 14,459 shares of the medical instruments supplier’s stock valued at $3,846,000 after acquiring an additional 39 shares in the last quarter. First Citizens Bank & Trust Co. boosted its holdings in Becton, Dickinson and by 4.1% in the fourth quarter. First Citizens Bank & Trust Co. now owns 1,016 shares of the medical instruments supplier’s stock worth $255,000 after purchasing an additional 40 shares in the last quarter. Blossom Wealth Management boosted its holdings in Becton, Dickinson and by 3.5% in the first quarter. Blossom Wealth Management now owns 1,192 shares of the medical instruments supplier’s stock worth $317,000 after purchasing an additional 40 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. boosted its holdings in Becton, Dickinson and by 1.1% in the first quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,805 shares of the medical instruments supplier’s stock worth $1,012,000 after purchasing an additional 40 shares in the last quarter. Finally, Dorsey & Whitney Trust CO LLC boosted its holdings in Becton, Dickinson and by 1.6% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 2,535 shares of the medical instruments supplier’s stock worth $675,000 after purchasing an additional 41 shares in the last quarter. 86.74% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and news, EVP David Hickey sold 475 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $265.00, for a total transaction of $125,875.00. Following the sale, the executive vice president now directly owns 3,331 shares of the company’s stock, valued at $882,715. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Becton, Dickinson and news, EVP David Hickey sold 475 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $265.00, for a total transaction of $125,875.00. Following the sale, the executive vice president now directly owns 3,331 shares of the company’s stock, valued at $882,715. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Samrat S. Khichi sold 9,185 shares of the company’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the sale, the executive vice president now directly owns 5,928 shares in the company, valued at $1,543,888.32. The disclosure for this sale can be found here. Insiders sold 19,160 shares of company stock valued at $5,036,751 over the last quarter. Corporate insiders own 0.50% of the company’s stock.

Becton, Dickinson and Stock Down 0.9 %

Shares of BDX opened at $254.32 on Monday. The company has a 50-day simple moving average of $251.96 and a 200-day simple moving average of $254.68. The firm has a market capitalization of $72.53 billion, a P/E ratio of 43.85, a P/E/G ratio of 3.33 and a beta of 0.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.90 and a current ratio of 1.35. Becton, Dickinson and Company has a 52 week low of $231.46 and a 52 week high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The business had revenue of $4.64 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same quarter in the prior year, the business earned $2.74 earnings per share. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. On average, equities research analysts expect that Becton, Dickinson and Company will post 11.31 earnings per share for the current year.

Becton, Dickinson and Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be given a $0.87 dividend. This represents a $3.48 annualized dividend and a yield of 1.37%. The ex-dividend date is Thursday, September 8th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 60.00%.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of recent research reports. Citigroup cut shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $265.00 to $235.00 in a report on Monday, July 11th. Stifel Nicolaus decreased their price target on shares of Becton, Dickinson and from $290.00 to $280.00 in a report on Monday, July 18th. Wells Fargo & Company upgraded shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price target for the company in a report on Friday, June 24th. Morgan Stanley decreased their price target on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a report on Friday, July 15th. Finally, The Goldman Sachs Group upped their price target on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a report on Tuesday, August 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $277.63.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.